It's never too soon to treat rheumatoid arthritis: finally, some supportive evidence

Emery, Paul; Duquenne, Laurence

doi:10.1016/s2665-9913(20)30103-x

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using HETs in the early stages of MS aims to decrease the clinically apparent and subclinical inflammatory activity that drives neuronal and brain volume loss (brain atrophy), preserve brain tissue and neurological reserve, and maximize long-term brain health [20,68]. This strategy is similar to early aggressive treatment approaches for other immune-mediated diseases, such as rheumatoid arthritis, which are known to improve long-term clinical outcomes [69]. The early HET approach encompasses both induction therapy and continuous treatment with high-efficacy DMTs.…”

Section: Treatment Strategy (Escalation Vs Early Het)mentioning

confidence: 99%

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

et al. 2022

View full text Add to dashboard Cite

There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensus guidelines offering differing recommendations, there is broad heterogeneity in how the DMTs are used in clinical practice. Choosing a DMT for newly diagnosed patients with MS is currently a topic of significant debate in MS care. Historically, an escalation approach to DMT was used for newly diagnosed patients with RRMS. However, the evidence for clinical benefits of early treatment with high-efficacy therapies (HETs) in this population is emerging. In this review, we provide an overview of the DMT options and MS treatment strategies, and discuss the clinical benefits of HETs (including ofatumumab, ocrelizumab, natalizumab, alemtuzumab, and cladribine) in the early stages of MS, along with safety concerns associated with these DMTs. By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient.

show abstract

Section: Treatment Strategy (Escalation Vs Early Het)mentioning

confidence: 99%